EANS-News: Epigenomics Appoints Thomas Taapken as New CFO, Effective April 1, 2011

Brings significant U.S. experience and strategic transactions
expertise

--------------------------------------------------------------------------------
Corporate news transmitted by euro adhoc. The issuer/originator is solely
responsible for the content of this announcement.
--------------------------------------------------------------------------------

Personnel/Molecular diagnostics

Subtitle: Brings significant U.S. experience and strategic
transactions expertise

Berlin, Germany, and Seattle, WA, USA, January 11, 2011 (euro adhoc)
- Epigenomics AG (Frankfurt Prime Standard: ECX), the cancer
molecular diagnosis company, today announced Dr. Thomas Taapken as
new Chief Financial Officer (CFO) succeeding the company's current
CFO Oliver Schacht, PhD, effective April 1st, 2011. As previously
announced in December 2010, Oliver Schacht will leave effective March
31st, 2011. Oliver Schacht and Thomas Taapken will work closely
together to ensure an ordered and structured transition during Q1
2011.

Taapken will join Epigenomics from Biotie Therapies Corp. (Finland),
where he currently holds the position of CFO and is a member of the
Executive Management Team. He was appointed to this position in 2008,
following a business combination between Biotie Therapies and elbion
NV, where Taapken had been CFO since 2005. His extensive
international experience in the life sciences industry includes
further positions as Investment Partner at DVC Deutsche Venture
Capital from 2003 to 2005 and San Francisco-based US venture capital
firm Burrill & Company from 1998-2002. He also worked several years
at Sanofi-Aventis in the United States and Germany, managing
corporate venture capital activities, as well as in the areas of
corporate & business development and research. Throughout his career,
he has been involved in numerous transactions spanning acquisitions,
mergers, divestitures and as well as private and public offerings.

On his appointment as CFO of Epigenomics, Thomas Taapken commented:
"I have been impressed with Epigenomics' transition from a
biotechnology start-up into one of the most innovative cancer
molecular diagnostic companies over the recent years, which is now
aiming to become a major commercial player in the molecular
diagnostic field. I very much look forward to contributing to its
success during the important next phase of Epigenomics' corporate
development."

Professor Dr. Rolf Krebs, Chairman of Epigenomics AG's Supervisory Board said:
"With Thomas' appointment, we have found the ideal CFO to bring Epigenomics to
the next level in realizing the full commercial potential of its groundbreaking
cancer diagnostics products. He brings in exactly the right skill set and
seasoned experience in the industry that we were looking for. He has an
outstanding track record of achievements in his previous positions and the
Supervisory Board believes he will be a great team contributor and driving force
in the Company's Management Team."

Geert Nygaard, Chief Executive Officer of Epigenomics added: "On behalf of the
entire Management Team I welcome Thomas as our new CFO. We share the same vision
of developing Epigenomics into a commercial success story in the cancer
diagnostics market and the addition of Thomas' transactional experience will be
instrumental in the continued development of the company. I look forward to
working with him."

Epigenomics also intends to strengthen its commercial operation in the US by
recruiting an experienced US-based marketing and sales executive to head the
U.S.-based operations, currently run by the departing CFO, and to lead the
transformation of that organization into a commercial molecular diagnostics
enterprise. With such an addition Epigenomics expects to be well-positioned to
drive its U.S. commercialization strategy.

-Ends-

Contact Epigenomics AG

Dr. Achim Plum
Sen. VP Corporate Development
Epigenomics AG
Tel +49 (0) 30 24345 368
pr@epigenomics.com
www.epigenomics.com

About Epigenomics

Epigenomics AG is a molecular diagnostics company with a focus on the
development of novel products for cancer. Using DNA methylation
biomarkers, Epigenomics' tests on the market and in development for
colorectal, lung, and prostate cancer aim at aiding in an earlier and
more accurate diagnosis of these diseases, thereby potentially
increasing the patient's chances of survival.

For development and global commercialization of IVD test products,
Epigenomics pursues a dual business strategy in which direct
commercialization of proprietary diagnostic test products is combined
with non-exclusive licensing to diagnostic industry players with
broad customer access. Strategic diagnostics industry partners
include Abbott Molecular, Sysmex Corporation, Quest Diagnostics
Incorporated, ARUP Laboratories, Inc., and Warnex Laboratories, Inc.
for diagnostics test products and services, and QIAGEN N.V. for
sample preparation solutions and research products.

The company is headquartered in Berlin, Germany, and has a wholly
owned subsidiary, Epigenomics Inc., in Seattle, WA, USA. For more
information, please visit Epigenomics' website at
www.epigenomics.com.

Epigenomics legal disclaimer. This communication expressly or
implicitly contains certain forward-looking statements concerning
Epigenomics AG and its business. Such statements involve certain
known and unknown risks, uncertainties and other factors which could
cause the actual results, financial condition, performance or
achievements of Epigenomics AG to be materially different from any
future results, performance or achievements expressed or implied by
such forward-looking statements. Epigenomics AG is providing this
communication as of this date and does not undertake to update any
forward-looking statements contained herein as a result of new
information, future events or otherwise.

end of announcement euro adhoc
--------------------------------------------------------------------------------

ots Originaltext: Epigenomics AG
Im Internet recherchierbar: http://www.presseportal.de

Further inquiry note:

Dr. Achim Plum
Sen. VP Corporate Development
Epigenomics AG
Tel: +49 30 24345 368
achim.plum@epigenomics.com

Branche: Biotechnology
ISIN: DE000A0BVT96
WKN: A0BVT9
Index: Prime All Share, Technology All Share
Börsen: Frankfurt / regulated dealing/prime standard
Berlin / free trade
Hamburg / free trade
Stuttgart / free trade
Düsseldorf / free trade
München / free trade